A global view of pulmonary hypertension

The Lancet Respiratory Medicine

Volumn 4, Issue 4, 2016, Pages 306-322

  Hoeper, Marius M ^a,b   Humbert, Marc ^c   Souza, Rogerio ^d   Idrees, Majdy ^e   Kawut, Steven M ^f   Sliwa Hahnle, Karen ^g,h   Jing, Zhi Cheng ⁱ   Gibbs, J Simon R ^j  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH)   (Germany)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e Prince Sultan Military Medical City   (Saudi Arabia)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ FUWAI HOSPITAL   (China)

^j NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALTITUDE; AORTA STENOSIS; CAUSAL ATTRIBUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; HEALTH CARE POLICY; HEART LEFT VENTRICLE FAILURE; HEMOGLOBINOPATHY; HUMAN; HYPOXIA; INFECTION; INTERSTITIAL LUNG DISEASE; PRIORITY JOURNAL; PUBLIC HEALTH; PULMONARY HYPERTENSION; REVIEW; RHEUMATIC HEART DISEASE; AGING; DETERIORATION; DEVELOPING COUNTRY; GLOBAL HEALTH; MORTALITY; TRENDS;

AGING; CLINICAL DETERIORATION; DEVELOPING COUNTRIES; GLOBAL HEALTH; HUMANS; HYPERTENSION, PULMONARY;

EID: 84960466895     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00543-3     Document Type: Review

References (182)

1. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013, 62(25 suppl):D42-D50.
2. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016, 37:67-119.
3. Moreira EM, Gall H, Leening MJ, et al. Prevalence of pulmonary hypertension in the general population: the Rotterdam study. PLoS One 2015, 10:e0130072.
4. Tuder RM, Archer SL, Dorfmüller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013, 62(25 suppl):D4-12.
5. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010, 36:549-555. the French Pulmonary Arterial Hypertension Network.
6. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987, 107:216-223.
7. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
8. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007, 30:1103-1110.
9. Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005, 95:199-203.
10. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007, 30:104-109.
11. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996, 335:609-616. the International Primary Pulmonary Hypertension Study Group.
12. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006, 173:1023-1030.
13. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010, 122:156-163.
14. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010, 137:376-387.
15. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012, 142:448-456.
16. McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013, 62(25 suppl):D51-D59.
17. Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest 2011, 139:128-137.
18. Escribano-Subias P, Blanco I, López-Meseguer M, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 2012, 40:596-603. the REHAP investigators.
19. Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012, 186:790-796.
20. Korsholm K, Andersen A, Kirkfeldt RE, Hansen KN, Mellemkjaer S, Nielsen-Kudsk JE Survival in an incident cohort of patients with pulmonary arterial hypertension in Denmark. Pulm Circ 2015, 5:364-369.
21. Hoeper MM, Huscher D, Pittrow D Incidence and prevalence of pulmonary arterial hypertension in Germany. Int J Cardiol 2016, 203:612-613.
22. Health and Social Care Information Centre. Fifth annual report: key findings from the National Audit of Pulmonary Hypertension of the UK, Channel Islands, Gibraltar and Isle of Man. Report for the audit period April 2013-March 2014.
23. Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007, 132:373-379.
24. Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 2011, 140:301-309.
25. Alves JL, Gavilanes F, Jardim C, et al. Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident Brazilian cases. Chest 2015, 147:495-501.
26. Idrees M, Alnajashi K, Abdulhameed J, et al. Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin. Ann Thorac Med 2015, 10:204-211. the Registry Taskforce SAPH.
27. Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2013, 62(25 suppl):D13-D21.
28. Girerd B, Montani D, Eyries M, et al. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 2010, 11:73.
29. Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD, Kawut SM Sex and haemodynamics in pulmonary arterial hypertension. Eur Respir J 2014, 43:523-530.
30. Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013, 168:871-880.
31. Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant 2011, 30:982-989.
32. Idrees M, Al-Najashi K, Khan A, et al. Pulmonary arterial hypertension in Saudi Arabia: Patients' clinical and physiological characteristics and hemodynamic parameters. A single center experience. Ann Thorac Med 2014, 9:209-215. the SAPH Registry Taskforce.
33. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014, 129:57-65.
34. Hao YJ, Jiang X, Zhou W, et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur Respir J 2014, 44:963-972.
35. Coghlan JG, Denton CP, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014, 73:1340-1349. the DETECT study group.
36. Al-Harbi A, Abdullah K, Al-Abdulkareem A, Alghamdi A, Al-Jahdali H Prevalence of portopulmonary hypertension among liver transplant candidates in a region highly endemic for viral hepatitis. Ann Transplant 2014, 19:1-5.
37. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology 2006, 44:1502-1510.
38. Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008, 48:196-203. the Pulmonary Vascular Complications of Liver Disease Study Group.
39. van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol 2011, 58:2241-2247.
40. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation 2014, 130:749-756.
41. Duffels MG, Engelfriet PM, Berger RM, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol 2007, 120:198-204.
42. Lowe BS, Therrien J, Ionescu-Ittu R, Pilote L, Martucci G, Marelli AJ Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011, 58:538-546.
43. Verheugt CL, Uiterwaal CS, van der Velde ET, et al. Mortality in adult congenital heart disease. Eur Heart J 2010, 31:1220-1229.
44. Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med 2002, 346:1212-1220.
45. Chitsulo L, Engels D, Montresor A, Savioli L The global status of schistosomiasis and its control. Acta Trop 2000, 77:41-51.
46. Colley DG, Bustinduy AL, Secor WE, King CH Human schistosomiasis. Lancet 2014, 383:2253-2264.
47. Lapa M, Dias B, Jardim C, et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation 2009, 119:1518-1523.
48. Papamatheakis DG, Mocumbi AO, Kim NH, Mandel J Schistosomiasis-associated pulmonary hypertension. Pulm Circ 2014, 4:596-611.
49. dos Santos Fernandes CJ, Jardim CV, Hovnanian A, et al. Survival in schistosomiasis-associated pulmonary arterial hypertension. J Am Coll Cardiol 2010, 56:715-720.
50. de Cleva R, Herman P, Pugliese V, et al. Prevalence of pulmonary hypertension in patients with hepatosplenic mansonic schistosomiasis-prospective study. Hepatogastroenterology 2003, 50:2028-2030.
51. Bertrand E, Dalger J, Ramiara JP, Renambot J, Attia Y Bilharzial pulmonary arterial hypertension. Clinical and hemodynamic study in 37 patients. Arch Mal Coeur Vaiss 1978, 71:216-221. (in French).
52. Watt G, Long GW, Calubaquib C, Ranoa CP Cardiopulmonary involvement rare in severe Schistosoma japonicum infection. Trop Geogr Med 1986, 38:233-239.
53. Speich R, Jenni R, Opravil M, Pfab M, Russi EW Primary pulmonary hypertension in HIV infection. Chest 1991, 100:1268-1271.
54. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008, 177:108-113.
55. Murray CJ, Ortblad KF, Guinovart C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 384:1005-1070.
56. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 386:743-800. Global Burden of Disease Study 2013 Collaborators.
57. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002, 106:3068-3072. the Framingham Heart Study.
58. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA 2006, 296:2209-2216.
59. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009, 53:1119-1126.
60. Kjaergaard J, Akkan D, Iversen KK, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 2007, 99:1146-1150.
61. Bui AL, Horwich TB, Fonarow GC Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011, 8:30-41.
62. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292:344-350.
63. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
64. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355:260-269.
65. Borlaug BA, Redfield MM Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 2011, 123:2006-2014.
66. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015, 46:903-975.
67. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001, 37:183-188.
68. Grigioni F, Potena L, Galiè N, et al. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant 2006, 25:1241-1246.
69. Miller WL, Grill DE, Borlaug BA Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail 2013, 1:290-299.
70. Gerges C, Gerges M, Lang MB, et al. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. Chest 2013, 143:758-766.
71. Bursi F, McNallan SM, Redfield MM, et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol 2012, 59:222-231.
72. Barbash IM, Escarcega RO, Minha S, et al. Prevalence and impact of pulmonary hypertension on patients with aortic stenosis who underwent transcatheter aortic valve replacement. Am J Cardiol 2015, 115:1435-1442.
73. Cam A, Goel SS, Agarwal S, et al. Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis. J Thorac Cardiovasc Surg 2011, 142:800-808.
74. Roselli EE, Abdel Azim A, Houghtaling PL, Jaber WA, Blackstone EH Pulmonary hypertension is associated with worse early and late outcomes after aortic valve replacement: implications for transcatheter aortic valve replacement. J Thorac Cardiovasc Surg 2012, 144:1067. 74.e2.
75. Ben-Dor I, Goldstein SA, Pichard AD, et al. Clinical profile, prognostic implication, and response to treatment of pulmonary hypertension in patients with severe aortic stenosis. Am J Cardiol 2011, 107:1046-1051.
76. O'Sullivan CJ, Wenaweser P, Ceylan O, et al. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv 2015, 8:e002358.
77. Mohammed SF, Hussain I, AbouEzzeddine OF, et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation 2014, 130:2310-2320.
78. Sakata Y, Shimokawa H Epidemiology of heart failure in Asia. Circ J 2013, 77:2209-2217.
79. Bocchi EA, Braga FG, Ferreira SM, et al. III Brazilian Guidelines on Chronic Heart Failure. Arq Bras Cardiol 2009, 93(suppl 1):3-70. the Sociedasde Brasileira de Cardiologia, (in Portuguese).
80. Makubi A, Hage C, Lwakatare J, et al. Contemporary aetiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: the prospective Tanzania Heart Failure (TaHeF) study. Heart 2014, 100:1235-1241.
81. Ogah OS, Sliwa K, Akinyemi JO, Falase AO, Stewart S Hypertensive heart failure in Nigerian Africans: insights from the Abeokuta Heart Failure Registry. J Clin Hypertens (Greenwich) 2015, 17:263-272.
82. Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med 2012, 172:1386-1394.
83. Stewart S, Wilkinson D, Hansen C, et al. Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation 2008, 118:2360-2367.
84. Bloomfield GS, Barasa FA, Doll JA, Velazquez EJ Heart failure in sub-Saharan Africa. Curr Cardiol Rev 2013, 9:157-173.
85. Ntusi NB, Mayosi BM Epidemiology of heart failure in sub-Saharan Africa. Expert Rev Cardiovasc Ther 2009, 7:169-180.
86. Stewart S, Mocumbi AO, Carrington MJ, Pretorius S, Burton R, Sliwa K A not-so-rare form of heart failure in urban black Africans: pathways to right heart failure in the Heart of Soweto Study cohort. Eur J Heart Fail 2011, 13:1070-1077.
87. Sliwa K, Davison BA, Mayosi BM, et al. Readmission and death after an acute heart failure event: predictors and outcomes in sub-Saharan Africa: results from the THESUS-HF registry. Eur Heart J 2013, 34:3151-3159.
88. Eveborn GW, Schirmer H, Heggelund G, Lunde P, Rasmussen K The evolving epidemiology of valvular aortic stenosis. The Tromsø study. Heart 2013, 99:396-400.
89. Barreto-Filho JA, Wang Y, Dodson JA, et al. Trends in aortic valve replacement for elderly patients in the United States, 1999-2011. JAMA 2013, 310:2078-2085.
90. Haub C Population Reference Bureau. World population aging: clocks illustrate growth in population under age 5 and over age 65 (accessed June 20, 2015). http://www.prb.org/Publications/Articles/2011/agingpopulationclocks.aspx.
91. Carapetis JR, Steer AC, Mulholland EK, Weber M The global burden of group A streptococcal diseases. Lancet Infect Dis 2005, 5:685-694.
92. Zühlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J 2015, 36:1115. 122a.
93. Sriharibabu M, Himabindu Y, Kabir Z Rheumatic heart disease in rural south India: A clinico-observational study. J Cardiovasc Dis Res 2013, 4:25-29.
94. Zhang W, Mondo C, Okello E, et al. Presenting features of newly diagnosed rheumatic heart disease patients in Mulago Hospital: a pilot study. Cardiovasc J Afr 2013, 24:28-33.
95. Sliwa K, Carrington M, Mayosi BM, Zigiriadis E, Mvungi R, Stewart S Incidence and characteristics of newly diagnosed rheumatic heart disease in urban African adults: insights from the heart of Soweto study. Eur Heart J 2010, 31:719-727.
96. Sliwa K, Johnson MR, Zilla P, Roos-Hesselink JW Management of valvular disease in pregnancy: a global perspective. Eur Heart J 2015, 36:1078-1089.
97. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006, 27:397-412.
98. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007, 370:741-750. the BOLD Collaborative Research Group.
99. Raherison C, Girodet PO Epidemiology of COPD. Eur Respir Rev 2009, 18:213-221.
100. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005, 366:1875-1881. the PLATINO Team.
101. Adeloye D, Basquill C, Papana A, Chan KY, Rudan I, Campbell H An estimate of the prevalence of COPD in Africa: a systematic analysis. COPD 2015, 12:71-81.
102. Uzaslan E, Mahboub B, Beji M, et al. The burden of chronic obstructive pulmonary disease in the Middle East and North Africa: results of the BREATHE study. Respir Med 2012, 106(suppl 2):S45-S59. the BREATHE Study Group.
103. COPD prevalence in 12 Asia-Pacific countries and regions: projections based on the COPD prevalence estimation model. Respirology 2003, 8:192-198. Regional COPD Working Group.
104. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006, 28:523-532.
105. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981, 36:752-758.
106. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002, 166:314-322. the National Emphysema Treatment Trial (NETT) Group.
107. Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, Christie JD Impact of pulmonary artery pressure on exercise function in severe COPD. Chest 2009, 136:412-419.
108. Minai OA, Fessler H, Stoller JK, et al. Clinical characteristics and prediction of pulmonary hypertension in severe emphysema. Respir Med 2014, 108:482-490. the NETT Research Group.
109. Cuttica MJ, Kalhan R, Shlobin OA, et al. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 2010, 104:1877-1882.
110. Portillo K, Torralba Y, Blanco I, et al. Pulmonary hemodynamic profile in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015, 10:1313-1320.
111. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998, 113:576-583.
112. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005, 127:1531-1536.
113. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172:189-194.
114. Chaouat A, Naeije R, Weitzenblum E Pulmonary hypertension in COPD. Eur Respir J 2008, 32:1371-1385.
115. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995, 107:1193-1198.
116. Andersen KH, Iversen M, Kjaergaard J, et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant 2012, 31:373-380.
117. World population by age and sex US Census Bureau, International Data BaseInternational Data Base, (accessed Aug 23, 2015). http://www.census.gov/idb/worldpopinfo.html.
118. Ohno S, Nakaya T, Bando M, Sugiyama Y Idiopathic pulmonary fibrosis-results from a Japanese nationwide epidemiological survey using individual clinical records. Respirology 2008, 13:926-928.
119. Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010, 137:129-137.
120. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014, 2:566-572.
121. Ley B, Collard HR Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 2013, 5:483-492.
122. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012, 21:355-361.
123. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006, 129:746-752.
124. Patel NM, Lederer DJ, Borczuk AC, Kawut SM Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007, 132:998-1006.
125. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007, 30:715-721.
126. Rivera-Lebron BN, Forfia PR, Kreider M, Lee JC, Holmes JH, Kawut SM Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis. Chest 2013, 144:564-570.
127. Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008, 76:288-294.
128. Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007, 131:650-656.
129. Kimura M, Taniguchi H, Kondoh Y, et al. Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration 2013, 85:456-463.
130. Gläser S, Obst A, Koch B, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis-the predictive value of exercise capacity and gas exchange efficiency. PLoS One 2013, 8:e65643.
131. Raghu G, Nathan SD, Behr J, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J 2015, 46:1370-1377.
132. Corte TJ, Wort SJ, Gatzoulis MA, Macdonald P, Hansell DM, Wells AU Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax 2009, 64:883-888.
133. Alhamad EH, Cal JG, Alfaleh HF, Alshamiri MQ, Alboukai AA, Alhomida SA Pulmonary hypertension in Saudi Arabia: a single center experience. Ann Thorac Med 2013, 8:78-85.
134. Moore LG, Niermeyer S, Zamudio S Human adaptation to high altitude: regional and life-cycle perspectives. Am J Phys Anthropol 1998, 107(suppl 27):25-64.
135. Aldashev AA, Sarybaev AS, Sydykov AS, et al. Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype. Am J Respir Crit Care Med 2002, 166:1396-1402.
136. Sui GJ, Liu YH, Cheng XS, et al. Subacute infantile mountain sickness. J Pathol 1988, 155:161-170.
137. Penaloza D, Arias-Stella J The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation 2007, 115:1132-1146.
138. Pasha MA, Newman JH High-altitude disorders: pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest 2010, 137(suppl):13S-19S.
139. Hoeper MM, Madani MM, Nakanishi N, Meyer B, Cebotari S, Rubin LJ Chronic thromboembolic pulmonary hypertension. Lancet Respir Med 2014, 2:573-582.
140. Dentali F, Donadini M, Gianni M, et al. Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. Thromb Res 2009, 124:256-258.
141. Becattini C, Agnelli G, Pesavento R, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 2006, 130:172-175.
142. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004, 350:2257-2264. the Thromboembolic Pulmonary Hypertension Study Group.
143. Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. Circulation 1999, 99:1325-1330.
144. White RH The epidemiology of venous thromboembolism. Circulation 2003, 107(suppl 1):I4-I8.
145. Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. Ann Thorac Surg 2012, 94:97-103.
146. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011, 124:1973-1981.
147. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008, 177:1122-1127.
148. Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 2011, 141:702-710.
149. Kawar B, Ellam T, Jackson C, Kiely DG Pulmonary hypertension in renal disease: epidemiology, potential mechanisms and implications. Am J Nephrol 2013, 37:281-290.
150. Sise ME, Courtwright AM, Channick RN Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney Int 2013, 84:682-692.
151. Navaneethan SD, Roy J, Tao K, et al. Prevalence, predictors, and outcomes of pulmonary hypertension in CKD. J Am Soc Nephrol 2015; pii: ASN.2014111111.
152. Baughman RP, Engel PJ, Taylor L, Lower EE Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010, 138:1078-1085.
153. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006, 129:1246-1252.
154. Le Pavec J, Lorillon G, Jaïs X, et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012, 142:1150-1157.
155. Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000, 161:216-223.
156. Elstein D, Klutstein MW, Lahad A, Abrahamov A, Hadas-Halpern I, Zimran A Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. Lancet 1998, 351:1544-1546.
157. den Bakker MA, Grünberg K, Boonstra A, van Hal PT, Hollak CE Pulmonary arterial hypertension with plexogenic arteriopathy in enzyme-substituted Gaucher disease. Histopathology 2012, 61:324-326.
158. Cottin V, Harari S, Humbert M, et al. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J 2012, 40:630-640. the Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).
159. Lee TM, Berman-Rosenzweig ES, Slonim AE, Chung WK Two cases of pulmonary hypertension associated with type III glycogen storage disease. JIMD Rep 2011, 1:79-82.
160. Aliyu ZY, Kato GJ, Taylor J, et al. Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and management. Am J Hematol 2008, 83:63-70.
161. Piel FB, Patil AP, Howes RE, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun 2010, 1:104.
162. Huttle A, Maestre GE, Lantigua R, Green NS Sickle cell in sickle cell disease in Latin America and the United States. Pediatr Blood Cancer 2015, 62:1131-1136.
163. Modell B, Darlison M, Birgens H, et al. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest 2007, 67:39-69.
164. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004, 350:886-895.
165. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011, 365:44-53.
166. Mehari A, Alam S, Tian X, et al. Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med 2013, 187:840-847.
167. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 2012, 39:112-118.
168. Castro O, Hoque M, Brown BD Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2003, 101:1257-1261.
169. Simonneau G, Parent F Pulmonary hypertension in patients with sickle cell disease: not so frequent but so different. Eur Respir J 2012, 39:3-4.
170. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA 2012, 307:1254-1256.
171. Du ZD, Roguin N, Milgram E, Saab K, Koren A Pulmonary hypertension in patients with thalassemia major. Am Heart J 1997, 134:532-537.
172. Farmakis D, Aessopos A Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked. Circulation 2011, 123:1227-1232.
173. Derchi G, Galanello R, Bina P, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study. Circulation 2014, 129:338-345. the Webthal Pulmonary Arterial Hypertension Group.
174. Aessopos A, Stamatelos G, Skoumas V, Vassilopoulos G, Mantzourani M, Loukopoulos D Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia. Chest 1995, 107:50-53.
175. Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005, 127:1523-1530.
176. Meloni A, Detterich J, Pepe A, Harmatz P, Coates TD, Wood JC Pulmonary hypertension in well-transfused thalassemia major patients. Blood Cells Mol Dis 2015, 54:189-194.
177. Aessopos A, Farmakis D, Hatziliami A, et al. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 2004, 73:359-366.
178. Crary SE, Ramaciotti C, Buchanan GR Prevalence of pulmonary hypertension in hereditary spherocytosis. Am J Hematol 2011, 86:E73-E76.
179. Jaïs X, Ioos V, Jardim C, et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 2005, 60:1031-1034.
180. World population aging: clocks illustrate growth in population under age 5 and over age 65 Population Reference Bureau, (assessed June 20, 2015). http://www.prb.org/Publications/Articles/2011/agingpopulationclocks.aspx.
181. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993, 85:892-897.
182. Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014, 130:2189-2208.